BCC Research Forecasts Neurology Market to Reach $94.8 Billion by 2029

News provided by

May 21, 2025, 14:22 ET

"Increased Prevalence of Chronic Neurological Conditions and Enhanced Healthcare Infrastructure Drive Neurology Market Growth in Unexplored Markets"

BOSTON, May 21, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Neurology Market: A BCC Research Overview" is estimated to increase from $67.3 billion in 2024 to $94.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.1% from 2024 through 2029.

This report covers the market's current and future potential and examines market drivers and constraints, pipeline medications, the competitive landscape, the regulatory picture, and the epidemiology of neurological disorders. The study segments the market by disease indications, including Parkinson's, Alzheimer's, psychotic disorders, epilepsy, autism, multiple sclerosis, and brain tumors, with therapeutic and regional analysis for each. It also profiles smarket participants and competitors across North America, Europe, Asia-Pacific, and the Rest of the World.

This report is significant at the present time because the global population has grown and aged over the past 30 years, increasing exposure to environmental, metabolic and lifestyle risk factors. Consequently, there has been a notable rise in neurological conditions such as stroke, Alzheimer's disease, other dementias, and meningitis. Prevalent neurological disorders include cerebrovascular, neurodegenerative, autoimmune, spinal cord issues, intracranial tumors, and craniocerebral trauma. The growing incidence of these conditions, alongside government initiatives and ongoing research, drives market growth in the neurological field.

The factors driving the market include:

Aging Population: As people live longer, more individuals are experiencing neurological disorders like dementia and Parkinson's disease, increasing the demand for treatments.

Rising Neurological Disorders: The global incidence of neurological conditions is growing due to longer life expectancies and better diagnosis, driving the need for improved healthcare services.

Awareness Initiatives: Governments and NGOs are raising awareness about neurological disorders, reducing stigma, and advocating for better prevention and treatment.

Research and Innovation: Ongoing research initiatives are leading to new technologies and treatments in neurology.

Request a sample copy of the global market for neurology report.

Report Synopsis

Report Metric	Details
Base year considered	2023
Forecast period considered	2024-2029
Base year market size	$63.0 billion
Market size forecast	$94.8 billion
Growth rate	CAGR of 7.1% for the forecast period of 2024-2029
Segments covered	Disease Indication, Region
Regions covered	North America, Europe, Asia-Pacific, Rest of the World
Countries covered	U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Denmark, Belgium, the Netherlands, Sweden, Russia, China, India, Japan, New Zealand, Singapore, Malaysia, Thailand, Indonesia, South Africa, GCC Countries, Brazil, Argentina, Colombia, Paraguay, and Peru
Market drivers	• Growing Geriatric Population with Neurological Disorders • Increasing Global Incidence of Neurological Disorders • Government and NGO Initiatives in Creating Awareness • Research Initiatives in Neurology

Interesting facts:

In 2024, biopharma company UCB announced that BRIVIACT (brivaracetam) had been approved for use as a monotherapy and adjunctive treatment for partial onset seizures in adult epileptic patients, with or without secondary generalization, by the Japanese Ministry of Health, Labour, and Welfare (MHLW). The European Medicine Agency (EMA) has validated a Type II application for epcoritamab (TEPKINLY) for the same indication.
In December 2024, H. Lundbeck A/S acquired Longboard Pharmaceuticals, a clinical-stage biopharmaceutical developer of innovative medications for neurological conditions. Lundbeck's acquisition of Longboard is a strategic milestone that advances its objective of developing a neuro-rare disease franchise.

Emerging startups:

Harmony Biosciences
Evox Therapeutics
QurAlis
Passage Bio

The report addresses the following questions:

What is the market's projected size and growth rate?
The global neurology market was valued at $63.0 billion in 2023 and is expected to reach $94.8 billion by the end of 2029, at a CAGR of 7.1% from 2024 to 2029.
What are the factors driving the growth of the market?
Government and NGO initiatives designed to increase awareness of the increasing global incidence of neurological disorders, the growing geriatric population with neurological disorders, and research initiatives in neurology.
What market segments are covered in the report?
The global neurology market is segmented based on disease indication and region.
Which disease indication segment will be dominant over the forecast period?
The multiple sclerosis segment will dominate the market for the next four years.
Which region has the largest market share?
North America holds the largest share of the market.

Market leaders include:

ABBVIE INC.
ALPHA COGNITION
BIOGEN
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB CO.
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
H. LUNDBECK A/S
LILLY
MERCK & CO. INC.
NOVARTIS AG
OTSUKA HOLDINGS CO. LTD.
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
UCB S.A.

Related Reports:

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets: This report focuses on biomarker tests for AD in the diagnostics segment, excluding cognitive tests and neuroimaging methods. The therapeutics segment covers only pharmacological treatments, excluding alternative treatments and off-label drug use. The market is segmented by test type, region, purpose, drug class, drug type, and disease stage. The report discusses clinical trials, innovations, opportunities, and the latest AD diagnostics and therapeutics trends.

Breakthrough Therapies: Market Dynamics and Investment Opportunities: This report explores the potential risks and benefits of breakthrough therapy designation (BTD), comparing fast-track drug development approaches and highlighting the opportunities and challenges in creating breakthrough therapies. It covers therapy areas for cardiovascular, neurology, rare diseases, and oncology, and analyzes leading companies, their products and their revenues.

Navigate Uncertainty with Confidence

In times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we're here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape—giving you the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That's why, for a limited time, we're offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights.

Purchase a copy of the report direct from BCC Research.

For further information or any of these reports or to make a purchase, contact [email protected].

About BCC Research

BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.

Contact Us

Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA

Email: [email protected]

Phone: +1 781-489-7301

For media inquiries, email [email protected] or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

Logo - https://mma.prnewswire.com/media/2183242/5332054/BCC_Research_Logo.jpg

SOURCE BCC Research LLC